PURPOSE: The aim of this study is to determine clinical and histopathological characteristics correlated to responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. PATIENTS AND METHODS: We studied primary tumor specimens with local advanced breast cancer from 40 patients. Patients received anthracycline-based chemotherapy. Neoadjuvant regimen consisted in 600 mg/m2 5-fluorouracil, 60 mg/m2 doxorubicin, and 600 mg/m2 cyclophosphamide (FAC). The World Health Organization criteria were used to classify the tumors. We performed immunohistochemical staining for ER, PgR, HER-2, PCNA (proliferation cell nuclear antigen), Ki-67, p53, and Bcl-2. Clinical and histopathological characteristics were associated with clinical response and histopathological changes induced by chemotherapy. RESULTS: The mean age was 47 +/- 14 yr. Twenty-three percent of patients were in stage IIB and 77% were in stages IIIA and IIIB. Seven percent of patients had progression of the disease. Stable disease was observed in 42% of patients and 45% had partial response. Only 7% of patients had a complete response. Factors associated with a better and major percentage of clinical response were the administration of doxorubicin-based chemotherapy, administration of more than three cycles, clinical N1, atypia, more than 10 mitosis per high-power field, moderate to severe SBR grade, and a major index of cellular proliferation. CONCLUSION: We found that tumors with large volumes, N2 node status, low cellular proliferation rate, positive immunoreactivity to p53, and low differentiation grade have a lower response to neoadjuvant chemotherapy with anthracycline. These patients could benefit from a different chemotherapy scheme to obtain a better control and resection.
PURPOSE: The aim of this study is to determine clinical and histopathological characteristics correlated to responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. PATIENTS AND METHODS: We studied primary tumor specimens with local advanced breast cancer from 40 patients. Patients received anthracycline-based chemotherapy. Neoadjuvant regimen consisted in 600 mg/m2 5-fluorouracil, 60 mg/m2 doxorubicin, and 600 mg/m2 cyclophosphamide (FAC). The World Health Organization criteria were used to classify the tumors. We performed immunohistochemical staining for ER, PgR, HER-2, PCNA (proliferation cell nuclear antigen), Ki-67, p53, and Bcl-2. Clinical and histopathological characteristics were associated with clinical response and histopathological changes induced by chemotherapy. RESULTS: The mean age was 47 +/- 14 yr. Twenty-three percent of patients were in stage IIB and 77% were in stages IIIA and IIIB. Seven percent of patients had progression of the disease. Stable disease was observed in 42% of patients and 45% had partial response. Only 7% of patients had a complete response. Factors associated with a better and major percentage of clinical response were the administration of doxorubicin-based chemotherapy, administration of more than three cycles, clinical N1, atypia, more than 10 mitosis per high-power field, moderate to severe SBR grade, and a major index of cellular proliferation. CONCLUSION: We found that tumors with large volumes, N2 node status, low cellular proliferation rate, positive immunoreactivity to p53, and low differentiation grade have a lower response to neoadjuvant chemotherapy with anthracycline. These patients could benefit from a different chemotherapy scheme to obtain a better control and resection.
Authors: P Collecchi; E Baldini; P Giannessi; A G Naccarato; A Passoni; G Gardin; M Roncella; G Evangelista; G Bevilacqua; P F Conte Journal: Eur J Cancer Date: 1998-10 Impact factor: 9.162
Authors: S M Swain; R A Sorace; C S Bagley; D N Danforth; J Bader; M N Wesley; S M Steinberg; M E Lippman Journal: Cancer Res Date: 1987-07-15 Impact factor: 12.701
Authors: Stephanie Geisler; Anne-Lise Børresen-Dale; Hilde Johnsen; Turid Aas; Jürgen Geisler; Lars Andreas Akslen; Gun Anker; Per Eystein Lønning Journal: Clin Cancer Res Date: 2003-11-15 Impact factor: 12.531
Authors: Lajos Pusztai; Savitri Krishnamurti; Jorge Perez Cardona; Nour Sneige; Francisco J Esteva; Marina Volchenok; Patricia Breitenfelder; Shu-Wan Kau; Shin Takayama; Stanislaw Krajewski; John C Reed; Robert C Bast; Gabriel N Hortobagyi Journal: Cancer Invest Date: 2004 Impact factor: 2.176
Authors: Paula Cabrera-Galeana; Wendy Muñoz-Montaño; Fernando Lara-Medina; Alberto Alvarado-Miranda; Victor Pérez-Sánchez; Cynthia Villarreal-Garza; R Marisol Quintero; Fany Porras-Reyes; Enrique Bargallo-Rocha; Ignacio Del Carmen; Alejandro Mohar; Oscar Arrieta Journal: Oncologist Date: 2018-02-28
Authors: Alberto Alvarado-Miranda; Oscar Arrieta; Carlos Gamboa-Vignolle; David Saavedra-Perez; Rafael Morales-Barrera; Enrique Bargallo-Rocha; Juan Zinser-Sierra; Victor Perez-Sanchez; Teresa Ramirez-Ugalde; Fernando Lara-Medina Journal: Radiat Oncol Date: 2009-07-11 Impact factor: 3.481
Authors: Marcus C Tan; Fatema Al Mushawah; Feng Gao; Rebecca L Aft; William E Gillanders; Timothy J Eberlein; Julie A Margenthaler Journal: Am J Surg Date: 2009-10 Impact factor: 2.565